Yarrow Bioscience Inc - Asset Resilience Ratio
Yarrow Bioscience Inc (YARW) has an Asset Resilience Ratio of 1.15% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read YARW total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Yarrow Bioscience Inc's Asset Resilience Ratio has changed over time. See Yarrow Bioscience Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Yarrow Bioscience Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see YARW total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $297.00K | 1.15% |
| Total Liquid Assets | $297.00K | 1.15% |
Asset Resilience Insights
- Limited Liquidity: Yarrow Bioscience Inc maintains only 1.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Yarrow Bioscience Inc Industry Peers by Asset Resilience Ratio
Compare Yarrow Bioscience Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Dyne Therapeutics Inc
NASDAQ:DYN |
Biotechnology | 20.28% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX |
Biotechnology | 0.00% |
|
LegoChem Biosciences Inc
KQ:141080 |
Biotechnology | 55.88% |
Annual Asset Resilience Ratio for Yarrow Bioscience Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Yarrow Bioscience Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 16.52% | $4.98 Million | $30.16 Million | -45.65pp |
| 2024-12-31 | 62.16% | $41.59 Million | $66.91 Million | -1.95pp |
| 2023-12-31 | 64.12% | $62.63 Million | $97.69 Million | +63.02pp |
| 2020-12-31 | 1.10% | $1.03 Million | $93.74 Million | -57.22pp |
| 2019-12-31 | 58.31% | $46.17 Million | $79.17 Million | -3.67pp |
| 2018-12-31 | 61.99% | $86.74 Million | $139.93 Million | -11.73pp |
| 2017-12-31 | 73.72% | $49.30 Million | $66.87 Million | +9.80pp |
| 2016-12-31 | 63.92% | $26.88 Million | $42.05 Million | -- |
About Yarrow Bioscience Inc
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based i… Read more